Phase 2 trial results for the investigational vaccine were presented at IDWeek 2026 in Washington, DC, as the phase 3 program is currently underway.
|Articles|November 11, 2022
News Roundup: November 7 to November 11
Author(s)Miranda Hester
Your weekly roundup of the latest news from Drug Topics®.
Advertisement
Tips for Tackling PBM Audits—Together
Working collaboratively can be key to either avoiding a PBM audit altogether or making the process as painless as possible.
Impact of Guideline Changes on Opioid Use in Childhood Cancer Survivors
Childhood cancer survivors are high risk of pain and in need of pain relief. Did 2016 guidelines for opioid prescribing change use in this group?
Tackling Pneumonia in the Pharmacy
Besides providing education and counseling, pharmacists play a key role in the administration of vaccines.
Improving Vaccine Uptake Requires More Than a ‘One Size Fits All’ Approach
Addressing hesitancy is more than just offering pertinent information.
Are Cannabinoids Key to Harm Reduction in Opioid Use Disorder?
Cannabinoids lack the habit-forming mechanism of action found in methadone and buprenorphine, unlocking new potential for the drug.
Advertisement
Related to this article
The finalized rule is another step in the right direction for pharmacies calling for reform due to underwater reimbursement and other PBM pressures.
Allison Schneider, MPH, provides a detailed update regarding pharmacies’ impact within Medicare price negotiations and the legislation further impacting businesses.
The US health department announced policies that will allow for the compounding of 6 key peptides in US pharmacies.
New survey data add to the evidence regarding the safe and effective route of administering both COVID-19 and flu vaccines simultaneously.
This episode breaks down how PBMs conduct inventory audits, the sourcing and timing issues that trigger recoupments, and how pharmacies can prepare and push back.
In part 2 of our discussion with Kimberly Kue-Tsemo, PharmD, she addresses the emergence of technology and the nuances behind its actual capabilities.
In part 2, Allison Schneider, MPH, discusses PBM and 340B reform that could compound pharmacies’ burden amid ongoing Medicare drug price negotiations.
Advertisement
Advertisement
Trending on Drug Topics
1
HHS Lets Pharmacies Compound Peptides as FDA Writes Official Rule
2
Updated Diabetes Consensus Shifts Focus from Glucose Control to Whole-Person Care
3
Pharmacies Face Persistent MFP Cash Crunch Amid PBM, 340B Shifts
4
COVID-19, Flu Shots Coadministered Are Well-Tolerated in Pregnancy
5